I crunch the numbers on COVID vaccines. No surprises … they’re going overwhelmingly to rich countries.

I feel like it’s December 2020.

Probablemente sientes que estamos inundados con información sobre la evolución de la pandemia de COVID-19. Sin embargo, nada mejor que manejar los datos uno mismo y analizarlos desde distintos puntos de vista. Creo que siempre hay alguien que observará algo en los datos que se nos ha escapado a millones de observadores y creo que cualquier aporte en esta emergencia mundial es valioso.

In July 2020, Europe PMC began indexing the full text of COVID-19 preprints. The initiative supported by Wellcome, the UK Medical Research Council, and Swiss National Science Foundation, has now made over 15,300 full text COVID-19 preprints searchable and free to read, alongside peer reviewed articles. Number of full text COVID-19 preprints in Europe PMC by month.

[More than 4,500 Research Square preprints discoverable alongside peer-reviewed research]{face=“"Open Sans", sans-serif” style=“font-size: 11pt; font-style: italic; white-space: pre-wrap;”} [Research Square’s collection of more than 4,500 full-text COVID-19 preprints have been indexed in Europe PMC, an open-access repository of more than 1 million biomedical research works.]{face=“"Open Sans", sans-serif” style=“font-size: 11pt;

[In this pandemic, researchers have responded by publishing results rapidly, often through preprints.]{style=“background-color: transparent; color: black; font-family: "arial"; font-style: normal; font-weight: 400; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;”} [In fact, up to half of the publications in Europe PMC on COVID-19 are preprints rather than peer-reviewed journal articles.

Along with life science publications, Europe PMC offers a way to search through biomedical grants from Europe PMC funders using the Grant Finder tool. Last year, Europe PMC partnered with the Medical Research Council (MRC), the UK Collaborative on Development Research (UKCDR) and the Global Research Collaboration for Infectious Disease Preparedness (GLoPID-R), to extend its search to include COVID-19 grant data from other funding organisations.

Gestern verkündeten die USA, den Schutz geistigen Eigentums für Covid-19-Impfstoffe aussetzen zu wollen. Wie sieht die Lage für offene Alternativen in der Entwicklung von Impfstoffen aus? Das analysieren Milena Leybold und Leonhard Dobusch: Nicht nur geistiges Eigentum ist wichtig – auch Fragen der Haftung und der Finanzierung sind maßgeblich.

Das EU-Parlament stimmt für eine zeitweise Aussetzung von Patentansprüchen für Covid-19-Impfstoffe. Der Bundestag beschließt neue Regelungen für Cookies. Der netzpolitische Rückblick der letzten Woche.

Mafalda Sandrini Some days ago, a friend of mine told me that while she was grocery shopping, a 60 to 70 years old man shouted at her because she was wearing a mask. She was shocked: how could the man not understand she wanted to protect him? “I could be a weapon to him”, she told me. My friend, as far as she knows, did not have the COVID-19 disease, but she claimed she could not know for sure.